QSAR, docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase-I

Journal of Chemometrics

Volumn 27, Issue 1-2, 2013, Pages 21-33

  Yadav, Dharmendra K ^a   Khan, Feroz ^a  

^a CSIR CENTRAL INSTITUTE OF MEDICINAL AND AROMATIC PLANTS   (India)

Author keywords

ADMET; Anticancer; Camptothecin; DNA Topo I; Docking; Drug likeness; QSAR

Indexed keywords

BINDING ENERGY; BODY FLUIDS; CHEMICAL BONDS; COMPUTATIONAL CHEMISTRY; DNA; LINEAR REGRESSION;

ADMET; ANTICANCER; CAMPTOTHECIN DERIVATIVES; CAMPTOTHECINS; DNA TOPOISOMERASE I; DOCKING; DRUG LIKENESS; MULTIPLE LINEAR REGRESSION METHOD; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP MODELING;

ELECTRON AFFINITY;

EID: 84874190175     PISSN: 08869383     EISSN: 1099128X     Source Type: Journal    
DOI: 10.1002/cem.2488     Document Type: Article

References (37)

1. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000; 287: 1969-73.
2. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 1966; 88: 3888-90.
3. Pan XD, Wang CY. Current status of camptothecin derivatives as natural antitumor agents]. Yao Xue Xue Bao 2003; 38: 715-20.
4. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst. 1994; 86: 836-42.
5. Verweij J. Topoisomerase I inhibitors and other new cytotoxic drugs. Eur. J. Cancer 1995; 31A: 828-30.
6. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
7. Sharma BK, Singh P, Shekhawat M, Sarbhai K, Prabhakar YS. Modelling of serotonin reuptake inhibitory and histamine H(3)antagonistic activity of piperazine and diazepane amides: QSAR rationales for co-optimization of the activity profiles. SAR QSAR Environ. Res. 2011; 22: 365-83.
8. Ebalunode JO, Zheng W, Tropsha A. Application of QSAR and shape pharmacophore modeling approaches for targeted chemical library design. Methods Mol. Biol. 2011; 685: 111-33.
9. Manoharan P, Vijayan RS, Ghoshal N. Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FB-QSSR, multi objective (MO-QSPR) and MIF studies. J. Comput. Aided Mol. Des. 2010; 24: 843-64.
10. Chung JY, Chung HW, Cho SJ, Hah JM, Cho AE. QM/MM based 3D QSAR models for potent B-Raf inhibitors. J. Comput. Aided Mol. Des. 2010; 24: 385-97.
11. Sawada S, Matsuoka S, Nokata K, Nagata H, Furuta T, Yokokura T, Miyasaka T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: a-ring modified and 7, 10-disubstituted camptothecins. Chem. Pharm. Bull. (Tokyo) 1991; 39: 3183-8.
12. Cragg GM, Newman DJ. A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J. Nat. Prod. 2004; 67: 232-44.
13. Carrigan SW, Fox PC, Wall ME, Wani MC, Bowen JP. Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents. J. Comput. Aided Mol. Des. 1997; 11: 71-78.
14. Yoon KJP, Krull EJ, Morton CL, Bornmann WG, Lee RE, Potter PM, Danks MK. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. Mol. Cancer Ther. 2003; 2: 1171-1181.
15. De Julian-Ortiz JV. Virtual Darwinian drug design: QSAR inverse problem, virtual combinatorial chemistry, and computational screening. Comb. Chem. High Throughput Screen. 2001; 4: 295-310.
16. Rawal RK, Solomon VR, Prabhakar YS, Katti SB, De Clercq E. Synthesis and QSAR studies on thiazolidinones as anti-HIV agents. Comb. Chem. High Throughput Screen. 2005; 8: 439-43.
17. Dudek AZ, Arodz T, Galvez J. Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Comb. Chem. High Throughput Screen. 2006; 9: 213-28.
18. Duchowicz PR, Castr EA. Partial order theory applied to QSPR-QSAR studies. Comb. Chem. High Throughput Screen. 2008; 11: 783-93.
19. Shanmugasundaram K, Rigby AC. Exploring novel target space: a need to partner high throughput docking and ligand-based similarity searches? Comb. Chem. High Throughput Screen. 2009; 12: 984-99.
20. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. U.S.A. 2002; 99: 15387-15392.
21. Clark MC. In what ways, if any, are child abusers different from other parents? Health Visit. 1989; 62: 268-70.
22. Kalani K, Yadav DK, Khan F, Srivastava SK, Suri N. Pharmacophore, QSAR, and ADME based semisynthesis and in vitro evaluation of ursolic acid analogs for anticancer activity. J. Mol. Model. 2012; 18: 3389-413.
23. Lu AJ, Zhang ZS, Zheng MY, Zou HJ, Luo XM, Jiang HL. 3D-QSAR study of 20 (S)-camptothecin analogs. Acta Pharmacol. Sin. 2007; 28: 307-314.
24. Yadav DK, Meena A, Srivastava A, Chanda D, Khan F, Chattopadhyay SK. Development of QSAR model for immunomodulatory activity of natural coumarinolignoids. Drug Des. Devel. Ther. 2010; 4: 173-86.
25. Meena A, Yadav DK, Srivastava A, Khan F, Chanda D, Chattopadhyay SK. In silico exploration of anti-inflammatory activity of natural coumarinolignoids. Chem. Biol. Drug Des. 2011; 78: 567-79.
26. Yadav DK, Khan F, Negi AS. Pharmacophore modeling, molecular docking, QSAR, and in silico ADMET studies of gallic acid derivatives for immunomodulatory activity. J. Mol. Model. 2012; 18: 2513-25.
27. Maurya A, Khan F, Bawankule DU, Yadav DK, Srivastava SK. QSAR, docking and in vivo studies for immunomodulatory activity of isolated triterpenoids from Eucalyptus tereticornis and Gentiana kurroo. Eur. J. Pharm. Sci. 2012; 47: 152-161.
28. Kumar S, Singh V, Tiwari M. QSAR modeling of the inhibition of reverse transcriptase enzyme with benzimidazolone analogs. Medicinal Chemistry Research 2011; 20: 1530-1541.
29. Kumar S, Singh V, Tiwari M. Quantitative structure activity relationship studies of sulfamide derivatives as carbonic anhydrase inhibitor: as antiglaucoma agents. Medicinal Chemistry 2007; 3: 379-386.
30. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001; 46: 3-26.
31. Zheng W, Tropsha A. Novel variable selection quantitative structure--property relationship approach based on the k-nearest-neighbor principle. J. Chem. Inf. Comput. Sci. 2000; 40: 185-94.
32. Shen M, Xiao Y, Golbraikh A, Gombar VK, Tropsha A. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. J. Med. Chem. 2003; 46: 3013-20.
33. Sharma BK, Singh P, Pilania P, Shekhawat M, Prabhakar YS. QSAR of 2-(4-methylsulphonylphenyl)pyrimidine derivatives as cyclooxygenase-2 inhibitors: simple structural fragments as potential modulators of activity. J. Enzyme Inhib. Med. Chem. 2012; 27: 249-60.
34. Pommier Y, Leo E, Zhang HL, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010; 17: 421-433.
35. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002; 45: 2615-2623.
36. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998; 279: 1504-13.
37. Ismail MM, Rateb HS, Hussein MM. Synthesis and docking studies of novel benzopyran-2-ones with anticancer activity. Eur. J. Med. Chem. 2010; 45: 3950-9.